872 related articles for article (PubMed ID: 32872332)
21. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
22. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
Bendjelid K; Giraud R; Von Düring S
Anaesth Crit Care Pain Med; 2020 Aug; 39(4):451-452. PubMed ID: 32653550
[No Abstract] [Full Text] [Related]
23. Resveratrol protects mice against SEB-induced acute lung injury and mortality by miR-193a modulation that targets TGF-β signalling.
Alghetaa H; Mohammed A; Sultan M; Busbee P; Murphy A; Chatterjee S; Nagarkatti M; Nagarkatti P
J Cell Mol Med; 2018 May; 22(5):2644-2655. PubMed ID: 29512867
[TBL] [Abstract][Full Text] [Related]
24. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus.
Xu P; Sun GD; Li ZZ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5797-5809. PubMed ID: 32495918
[TBL] [Abstract][Full Text] [Related]
26. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
Kaye RJ
Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
[TBL] [Abstract][Full Text] [Related]
27. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.
Wu C; Hou D; Du C; Cai Y; Zheng J; Xu J; Chen X; Chen C; Hu X; Zhang Y; Song J; Wang L; Chao YC; Feng Y; Xiong W; Chen D; Zhong M; Hu J; Jiang J; Bai C; Zhou X; Xu J; Song Y; Gong F
Crit Care; 2020 Nov; 24(1):643. PubMed ID: 33172477
[TBL] [Abstract][Full Text] [Related]
28. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
30. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
[No Abstract] [Full Text] [Related]
31. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.
Leist SR; Dinnon KH; Schäfer A; Tse LV; Okuda K; Hou YJ; West A; Edwards CE; Sanders W; Fritch EJ; Gully KL; Scobey T; Brown AJ; Sheahan TP; Moorman NJ; Boucher RC; Gralinski LE; Montgomery SA; Baric RS
Cell; 2020 Nov; 183(4):1070-1085.e12. PubMed ID: 33031744
[TBL] [Abstract][Full Text] [Related]
32. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
33. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
[TBL] [Abstract][Full Text] [Related]
34. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.
Hasan SS; Capstick T; Ahmed R; Kow CS; Mazhar F; Merchant HA; Zaidi STR
Expert Rev Respir Med; 2020 Nov; 14(11):1149-1163. PubMed ID: 32734777
[TBL] [Abstract][Full Text] [Related]
35. The immune system and COVID-19: Friend or foe?
Yazdanpanah F; Hamblin MR; Rezaei N
Life Sci; 2020 Sep; 256():117900. PubMed ID: 32502542
[TBL] [Abstract][Full Text] [Related]
36. COVID-19: In the Eye of the Cytokine Storm.
de la Rica R; Borges M; Gonzalez-Freire M
Front Immunol; 2020; 11():558898. PubMed ID: 33072097
[TBL] [Abstract][Full Text] [Related]
37. Fibrinolytic therapy in patients with COVID-19 and acute respiratory distress syndrome: Is this a feasible approach?
Savioli F; Rocha L; Góis A; Nakano LC
J Trauma Acute Care Surg; 2020 Dec; 89(6):e187-e188. PubMed ID: 32868539
[No Abstract] [Full Text] [Related]
38. Dehydrozingerone ameliorates Lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress via modulating the MAPK/NF-κB pathway.
Tirunavalli SK; Gourishetti K; Kotipalli RSS; Kuncha M; Kathirvel M; Kaur R; Jerald MK; Sistla R; Andugulapati SB
Phytomedicine; 2021 Nov; 92():153729. PubMed ID: 34517257
[TBL] [Abstract][Full Text] [Related]
39. Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension.
Cure E; Cumhur Cure M; Vatansev H
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972015. PubMed ID: 33169637
[No Abstract] [Full Text] [Related]
40. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
